Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

194 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Life for patients with myelofibrosis: the physical, emotional and financial impact, collected using narrative medicine-Results from the Italian 'Back to Life' project.
Palandri F, Benevolo G, Iurlo A, Abruzzese E, Carella AM, Paoli C, Palumbo GA, Bonifacio M, Cilloni D, Andriani A, Guarini A, Turri D, Elli EM, Falcone A, Anaclerico B, Musto P, Di Renzo N, Tiribelli M, Zambello R, Spinosa C, Ricco A, Raucci L, Martino B, Annunziata M, Pascale S, Liberati AM, La Nasa G, Maffioli M, Breccia M, Pugliese N, Betti S, Giglio G, Cappuccio A, Reale L. Palandri F, et al. Qual Life Res. 2018 Jun;27(6):1545-1554. doi: 10.1007/s11136-018-1827-2. Epub 2018 Mar 8. Qual Life Res. 2018. PMID: 29520559 Free article.
Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, philadelphia-positive chronic myeloid leukemia: the GIMEMA Working Party on CML.
Palandri F, Iacobucci I, Martinelli G, Amabile M, Poerio A, Testoni N, Soverini S, Castagnetti F, De Vivo A, Breccia M, Specchia G, Abruzzese E, Martino B, Cilloni D, Saglio G, Pane F, Liberati AM, Rosti G, Baccarani M; GIMEMA Working Party on CML. Palandri F, et al. J Clin Oncol. 2008 Jan 1;26(1):106-11. doi: 10.1200/JCO.2007.13.2373. J Clin Oncol. 2008. PMID: 18165644
Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-alpha: 5-year outcome.
Palandri F, Iacobucci I, Castagnetti F, Testoni N, Poerio A, Amabile M, Breccia M, Intermesoli T, Iuliano F, Rege-Cambrin G, Tiribelli M, Miglino M, Pane F, Saglio G, Martinelli G, Rosti G, Baccarani M; GIMEMA Working Party on CML. Palandri F, et al. Haematologica. 2008 May;93(5):770-4. doi: 10.3324/haematol.12265. Epub 2008 Mar 26. Haematologica. 2008. PMID: 18367490 Free article. Clinical Trial.
The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-up.
Palandri F, Castagnetti F, Alimena G, Testoni N, Breccia M, Luatti S, Rege-Cambrin G, Stagno F, Specchia G, Martino B, Levato L, Merante S, Liberati AM, Pane F, Saglio G, Alberti D, Martinelli G, Baccarani M, Rosti G. Palandri F, et al. Haematologica. 2009 Feb;94(2):205-12. doi: 10.3324/haematol.13529. Epub 2009 Jan 14. Haematologica. 2009. PMID: 19144656 Free PMC article. Clinical Trial.
Treatment of Philadelphia-positive chronic myeloid leukemia with imatinib: importance of a stable molecular response.
Palandri F, Iacobucci I, Soverini S, Castagnetti F, Poerio A, Testoni N, Alimena G, Breccia M, Rege-Cambrin G, Tiribelli M, Varaldo R, Abruzzese E, Martino B, Luciano L, Pane F, Saglio G, Martinelli G, Baccarani M, Rosti G. Palandri F, et al. Clin Cancer Res. 2009 Feb 1;15(3):1059-63. doi: 10.1158/1078-0432.CCR-08-1195. Clin Cancer Res. 2009. PMID: 19188180 Clinical Trial.
Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors.
Soverini S, Gnani A, Colarossi S, Castagnetti F, Abruzzese E, Paolini S, Merante S, Orlandi E, de Matteis S, Gozzini A, Iacobucci I, Palandri F, Gugliotta G, Papayannidis C, Poerio A, Amabile M, Cilloni D, Rosti G, Baccarani M, Martinelli G. Soverini S, et al. Among authors: palandri f. Blood. 2009 Sep 3;114(10):2168-71. doi: 10.1182/blood-2009-01-197186. Epub 2009 Jul 9. Blood. 2009. PMID: 19589924 Free article.
Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia.
Rosti G, Palandri F, Castagnetti F, Breccia M, Levato L, Gugliotta G, Capucci A, Cedrone M, Fava C, Intermesoli T, Cambrin GR, Stagno F, Tiribelli M, Amabile M, Luatti S, Poerio A, Soverini S, Testoni N, Martinelli G, Alimena G, Pane F, Saglio G, Baccarani M; GIMEMA CML Working Party. Rosti G, et al. Among authors: palandri f. Blood. 2009 Dec 3;114(24):4933-8. doi: 10.1182/blood-2009-07-232595. Epub 2009 Oct 12. Blood. 2009. PMID: 19822896 Free article. Clinical Trial.
The response to imatinib and interferon-alpha is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase.
Palandri F, Castagnetti F, Iacobucci I, Martinelli G, Amabile M, Gugliotta G, Poerio A, Testoni N, Breccia M, Bocchia M, Crugnola M, Rege-Cambrin G, Martino B, Pierri I, Radaelli F, Specchia G, Pane F, Saglio G, Rosti G, Baccarani M. Palandri F, et al. Haematologica. 2010 Aug;95(8):1415-9. doi: 10.3324/haematol.2009.021246. Epub 2010 Mar 19. Haematologica. 2010. PMID: 20305139 Free PMC article.
Deletions of the derivative chromosome 9 do not influence the response and the outcome of chronic myeloid leukemia in early chronic phase treated with imatinib mesylate: GIMEMA CML Working Party analysis.
Castagnetti F, Testoni N, Luatti S, Marzocchi G, Mancini M, Kerim S, Giugliano E, Albano F, Cuneo A, Abruzzese E, Martino B, Palandri F, Amabile M, Iacobucci I, Alimena G, Pane F, Martinelli G, Saglio G, Baccarani M, Rosti G. Castagnetti F, et al. Among authors: palandri f. J Clin Oncol. 2010 Jun 1;28(16):2748-54. doi: 10.1200/JCO.2009.26.7963. Epub 2010 May 3. J Clin Oncol. 2010. PMID: 20439635 Clinical Trial.
Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party.
Gugliotta G, Castagnetti F, Palandri F, Breccia M, Intermesoli T, Capucci A, Martino B, Pregno P, Rupoli S, Ferrero D, Gherlinzoni F, Montefusco E, Bocchia M, Tiribelli M, Pierri I, Grifoni F, Marzocchi G, Amabile M, Testoni N, Martinelli G, Alimena G, Pane F, Saglio G, Baccarani M, Rosti G; Gruppo Italiano Malattie Ematologiche dell'Adulto CML Working Party. Gugliotta G, et al. Among authors: palandri f. Blood. 2011 May 26;117(21):5591-9. doi: 10.1182/blood-2010-12-324228. Epub 2011 Mar 30. Blood. 2011. PMID: 21450900 Free article.
194 results